TrialJAMA neurology2025

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.

Eline M E Coerver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.